1. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial 
PD MED Collaborative Group 
The Lancet 
Volume 384, Issue 9949, Pages (September 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
MAOBI=monoamine oxidase type B inhibitors. COMTI=catechol-O-methyl transferase inhibitors. *Reasons for discontinuing drug class are not mutually exclusive, some patients had more than one reason for stopping drug class usually side-effects and absence of efficacy. †14 patients withdrew or were lost to follow-up then later died (five for levodopa group, eight for dopamine agonist, one for MAOBI). ‡Other reason normally comorbidity.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Proportion of patients stopping treatment with allocated drug class
MAOBI=monoamine oxidase type B inhibitors.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Mean levodopa equivalent dose (LED; mg per day) by allocated treatment
MAOBI=monoamine oxidase type B inhibitors.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

5. Figure 4
39-item patient-rated Parkinson's disease questionnaire mobility score (A) and summary index (B) with time in levodopa and levodopa-sparing groups
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

6. Figure 5
Risk of developing dyskinesia in levodopa and levodopa-sparing groups
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

7. Figure 6
39-item patient-rated Parkinson's disease questionnaire mobility score (A) and summary index (B) with time in dopamine agonist and MAOBI groups
MAOBI=monoamine oxidase type B inhibitors.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions